Dare Bioscience | Investor Presentation Deck | 27 slides — playbook

Dare Bioscience | Investor Presentation Deck | 27 slides

Daré Bioscience · 2023-07

arc beats above · slides in the middle · loops below · scroll → 1 LOOPS

Deck intelligence map

3

coverage by narrative range · generated from this deck JSON

Narrative range 11 total

Metadata

Components

Metrics

Tools

Frameworks

Beats

Loops

Problem (Identify pain) 6 slides 100% 6/6 slides 100% 6/6 slides · 32 hits

— 0/6 slides

50% 3/6 slides · 4 hits 50% 3/6 slides 100% 6/6 slides 100% 6/6 slides Agitate (Make it worse) 2 slides 100% 2/2 slides 100% 2/2 slides · 5 hits

— 0/2 slides

50% 1/2 slides

— 0/2 slides

100% 2/2 slides 100% 2/2 slides Solution (Provide relief) 3 slides 100% 3/3 slides 100% 3/3 slides · 12 hits

— 0/3 slides

33.3% 1/3 slides

— 0/3 slides

100% 3/3 slides

— 0/3 slides

Slide inventory

27

every slide · same image gating as the playbook

01

The slide uses the etymology of the company name 'Daré' to frame their mission.inspire_vision

Open slide detail

02

other

Open slide detail

03

The slide uses a Gantt-style chart to map product development stages from pre-clinical to FDA approval.plan_implementation

Open slide detail

04

Includes professional credentials, leadership roles, and publication counts for both presenters.other

Open slide detail

05

The slide uses a high-contrast blue box to highlight the core product value proposition.present_solution

Open slide detailBeat · Solution (Provide relief)

06

Highlights the repurposing of the active ingredient in Viagra for a new indication with no current FDA-approved treatments.present_solution

Open slide detailBeat · Solution (Provide relief)

07

front_matter

Open slide detailBeat · Solution (Provide relief)

08

The slide uses a comparison framework to contrast existing treatments for other conditions with the lack of treatments for FSAD.frame_problem

Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction

09

This slide outlines regulatory requirements for clinical trial design, including placebo run-in periods, patient population definition, PRO instruments, and pricite_precedent

Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction

10

transition

Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction

11

Includes a visual comparison indicating FSAD is not equal to HSDD.frame_problem

Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction

12

Uses medical diagnostic criteria (DSM) to frame the business opportunity by analogy.compare_peers

Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction

13

The slide uses a bulleted list structure to categorize the patient experience into physical symptoms, motivations, emotional impact, and psychological concerns.frame_problem

Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction

14

Includes a highlighted section emphasizing the 10 million women actively seeking treatment.size_opportunity

Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction

15

transition

Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction

16

Includes yellow highlighting on key endpoint descriptions.present_framework

Open slide detail

17

The slide uses a funnel-like diagram to represent the patient recruitment and study flow.plan_implementation

Open slide detail

18

The table tracks patient flow from the single-blind run-in period through various analysis sets (ITT, SAS, PP).analyze_data

Open slide detail

19

Clinical trial safety data summary.analyze_data

Open slide detail

20

TEAE = Treatment-Emergent Adverse Event. Data shows comparable safety profiles between treatment and placebo.analyze_data

Open slide detail

21

TEAE = Treatment-Emergent Adverse Event; IP = Investigational Product.analyze_data

Open slide detail

22

Includes yellow highlighting on key phrases.show_traction

Open slide detail

23

The slide highlights statistically significant and near-significant improvements across five key sexual health domains.show_traction

Open slide detail

24

Includes yellow highlighting on key phrases. Mentions n=30 sub-group.analyze_data

Open slide detail

25

Focuses on regulatory strategy and clinical trial design parameters for Phase 3.plan_implementation

Open slide detail

26

state_next_steps

Open slide detail

27

The slide uses the company name 'Daré' as a linguistic anchor for its mission.inspire_vision

Open slide detail